drugset / Trial / NCT05172934

Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy Pilot Trial

NCT05172934

Phase 2 Completed 20 enrolled ProMedica Health System Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

Prospective, single center, non-randomized, pilot study to assess the feasibility of IA TNK following standard of care mechanical thrombectomy (MT) in patients with AIS. Participants will receive IA TNK after achieving mTICI 2b or 2c reperfusion with standard of care MT. Patients enrolled into the study will be followed for 3 months after treatment with IA TNK.

Timeline

Start
2022-03-15
Primary completion
2023-09-12
Completion
2023-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenecteplase Protein / enzyme biologic 4.5 mg Other

Indications